Cargando…

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic k...

Descripción completa

Detalles Bibliográficos
Autores principales: Saijo, Yuto, Okada, Hiroshi, Hata, Shinnosuke, Nakajima, Hanako, Kitagawa, Nobuko, Okamura, Takuro, Osaka, Takafumi, Kitagawa, Noriyuki, Majima, Saori, Senmaru, Takafumi, Ushigome, Emi, Nakanishi, Naoko, Hamaguchi, Masahide, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672375/
https://www.ncbi.nlm.nih.gov/pubmed/38002608
http://dx.doi.org/10.3390/jcm12226993
_version_ 1785140376462426112
author Saijo, Yuto
Okada, Hiroshi
Hata, Shinnosuke
Nakajima, Hanako
Kitagawa, Nobuko
Okamura, Takuro
Osaka, Takafumi
Kitagawa, Noriyuki
Majima, Saori
Senmaru, Takafumi
Ushigome, Emi
Nakanishi, Naoko
Hamaguchi, Masahide
Fukui, Michiaki
author_facet Saijo, Yuto
Okada, Hiroshi
Hata, Shinnosuke
Nakajima, Hanako
Kitagawa, Nobuko
Okamura, Takuro
Osaka, Takafumi
Kitagawa, Noriyuki
Majima, Saori
Senmaru, Takafumi
Ushigome, Emi
Nakanishi, Naoko
Hamaguchi, Masahide
Fukui, Michiaki
author_sort Saijo, Yuto
collection PubMed
description Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic ketoacidosis, resulting in drug discontinuation. Herein, we aimed to determine the reasons for discontinuing treatment with SGLT2is among Japanese patients with diabetes. This retrospective cohort study enrolled 766 patients with diabetes who had initiated SGLT2is between January 2014 and September 2021. The follow-up period was 2 years from the initiation of the SGLT2is. Overall, 97 patients (12.7%) discontinued the SGLT2is during the follow-up period. The most common reasons for discontinuing the SGLT2is were frequent urination (19.6%), followed by genital infection (11.3%), improved glycemic control (10.6%), and renal dysfunction (8.2%). A comparison of the characteristics between the continuation and the discontinuation group was conducted, excluding those who discontinued the SGLT2is because of improved glycemic control. The patients in the discontinuation group (68 [55–75] years) were older than those in the continuation group (64 [53–71] years; p = 0.003). Importantly, we found no significant association between diabetes duration, diabetic control, renal function, or complications of diabetes in both groups. This real-world study revealed that frequent urination was the most common reason underlying SGLT2i discontinuation among Japanese patients with diabetes. To avoid discontinuation, precautions against various factors that may cause frequent urination must be implemented.
format Online
Article
Text
id pubmed-10672375
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106723752023-11-09 Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study Saijo, Yuto Okada, Hiroshi Hata, Shinnosuke Nakajima, Hanako Kitagawa, Nobuko Okamura, Takuro Osaka, Takafumi Kitagawa, Noriyuki Majima, Saori Senmaru, Takafumi Ushigome, Emi Nakanishi, Naoko Hamaguchi, Masahide Fukui, Michiaki J Clin Med Article Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic ketoacidosis, resulting in drug discontinuation. Herein, we aimed to determine the reasons for discontinuing treatment with SGLT2is among Japanese patients with diabetes. This retrospective cohort study enrolled 766 patients with diabetes who had initiated SGLT2is between January 2014 and September 2021. The follow-up period was 2 years from the initiation of the SGLT2is. Overall, 97 patients (12.7%) discontinued the SGLT2is during the follow-up period. The most common reasons for discontinuing the SGLT2is were frequent urination (19.6%), followed by genital infection (11.3%), improved glycemic control (10.6%), and renal dysfunction (8.2%). A comparison of the characteristics between the continuation and the discontinuation group was conducted, excluding those who discontinued the SGLT2is because of improved glycemic control. The patients in the discontinuation group (68 [55–75] years) were older than those in the continuation group (64 [53–71] years; p = 0.003). Importantly, we found no significant association between diabetes duration, diabetic control, renal function, or complications of diabetes in both groups. This real-world study revealed that frequent urination was the most common reason underlying SGLT2i discontinuation among Japanese patients with diabetes. To avoid discontinuation, precautions against various factors that may cause frequent urination must be implemented. MDPI 2023-11-09 /pmc/articles/PMC10672375/ /pubmed/38002608 http://dx.doi.org/10.3390/jcm12226993 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saijo, Yuto
Okada, Hiroshi
Hata, Shinnosuke
Nakajima, Hanako
Kitagawa, Nobuko
Okamura, Takuro
Osaka, Takafumi
Kitagawa, Noriyuki
Majima, Saori
Senmaru, Takafumi
Ushigome, Emi
Nakanishi, Naoko
Hamaguchi, Masahide
Fukui, Michiaki
Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
title Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
title_full Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
title_fullStr Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
title_full_unstemmed Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
title_short Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
title_sort reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: the kamogawa-a study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672375/
https://www.ncbi.nlm.nih.gov/pubmed/38002608
http://dx.doi.org/10.3390/jcm12226993
work_keys_str_mv AT saijoyuto reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT okadahiroshi reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT hatashinnosuke reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT nakajimahanako reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT kitagawanobuko reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT okamuratakuro reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT osakatakafumi reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT kitagawanoriyuki reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT majimasaori reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT senmarutakafumi reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT ushigomeemi reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT nakanishinaoko reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT hamaguchimasahide reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy
AT fukuimichiaki reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy